Published in Melanoma Res on August 01, 2016
BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy. Onco Targets Ther (2016) 0.75
Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol (2017) 0.75
The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 9.90
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2010) 6.15
Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol (2011) 2.00
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol (2005) 1.54
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer (2013) 1.52
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26
Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys (2013) 1.08
Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol (2013) 1.03
Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer (2011) 0.98
Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol (2013) 0.96
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol (2017) 0.94
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol (2014) 0.89
Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol (2014) 0.87
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2014) 0.87
Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol (2015) 0.85
Principles of therapeutic drug monitoring. Handb Exp Pharmacol (2011) 0.83
LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol (2014) 0.83
Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg (2015) 0.82
Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res (2014) 0.81
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
The importance of the conformality, heterogeneity, and gradient indices in evaluating Gamma Knife radiosurgery treatment plans for intracranial meningiomas. Int J Radiat Oncol Biol Phys (2011) 2.03
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry (2003) 1.90
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (2012) 1.68
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
The 21-gene recurrence score and locoregional recurrence in breast cancer patients. Ann Surg Oncol (2014) 1.40
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother (2009) 1.36
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Patent foramen ovale and cryptogenic stroke. N Engl J Med (2013) 1.17
The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys (2011) 1.04
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol (2017) 0.94
Elective versus Therapeutic Neck Dissection in Oral Cancer. N Engl J Med (2015) 0.92
Utility of lymph node assessment for atypical spitzoid melanocytic neoplasms. Ann Surg Oncol (2010) 0.92
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med (2014) 0.91
Breast reconstruction and post-mastectomy radiation practice. Radiat Oncol (2013) 0.90
Surface dose investigation of the flattening filter-free photon beams. Int J Radiat Oncol Biol Phys (2012) 0.90
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med (2012) 0.87
Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol (2014) 0.87
Rising incidence of mucosal melanoma of the head and neck in the United States. J Skin Cancer (2012) 0.87
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol (2014) 0.86
Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys (2013) 0.86
Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol (2015) 0.86
Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother (2015) 0.86
Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance. Mod Pathol (2002) 0.85
Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol (2013) 0.85
Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol (2015) 0.85
The emerging role of radiotherapy for desmoplastic melanoma and implications for future research. Melanoma Res (2015) 0.84
Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer. J Am Coll Radiol (2012) 0.84
Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer (2013) 0.83
The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J Neurooncol (2003) 0.83
Comparison of image-guided radiotherapy technologies for prostate cancer. Am J Clin Oncol (2014) 0.83
Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys (2002) 0.83
Plaque brachytherapy for uveal melanoma: a vision prognostication model. Int J Radiat Oncol Biol Phys (2012) 0.82
Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional Analysis. Neurosurgery (2016) 0.82
Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw (2013) 0.81
Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res (2011) 0.81
Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. Leuk Lymphoma (2013) 0.80
Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy. Ann Surg Oncol (2013) 0.79
The non-Gaussian nature of prostate motion based on real-time intrafraction tracking. Int J Radiat Oncol Biol Phys (2013) 0.79
Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys (2013) 0.79
Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role? Oncologist (2012) 0.78
Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. J Vasc Interv Radiol (2012) 0.78
The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer (2013) 0.78
Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am (2011) 0.78
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology (2013) 0.78
Radiation therapy and neutropenia. Curr Probl Cancer (2015) 0.77
Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. Am J Clin Oncol (2017) 0.77
Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma (2014) 0.77
The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res (2016) 0.76
Complete response to high-dose IL-2 and enhanced IFNγ+Th17 : TREG ratio in a melanoma patient. Melanoma Res (2016) 0.76
A model and nomogram to predict tumor site origin for squamous cell cancer confined to cervical lymph nodes. Cancer (2014) 0.75
Current and planned multicenter trials for patients with primary or metastatic melanoma. J Surg Oncol (2011) 0.75
Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J (2010) 0.75
Respiratory-induced prostate motion using wavelet decomposition of the real-time electromagnetic tracking signal. Int J Radiat Oncol Biol Phys (2013) 0.75
Emesis as a Screening Diagnostic for Low Dose Rate (LDR) Total Body Radiation Exposure. Health Phys (2016) 0.75
Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma. J Pediatr Hematol Oncol (2015) 0.75
In reply to Marks. Int J Radiat Oncol Biol Phys (2013) 0.75
Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res (2016) 0.75
The Effect of Transition Clinics on Knowledge of Diagnosis and Perception of Risk in Young Adult Survivors of Childhood Cancer. J Pediatr Hematol Oncol (2016) 0.75
Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients. J Immunother (2016) 0.75
In regard to Roberge et al. Int J Radiat Oncol Biol Phys (2012) 0.75
Plasma homocysteine and immune activation in patients with malignant melanoma undergoing treatment with IFN-alpha. J Interferon Cytokine Res (2004) 0.75
Truth in Advertising: Do Clinical Trial Publications Tell It All? J Natl Compr Canc Netw (2017) 0.75
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res (2017) 0.75
Reassessing dose constraints of organs at risk in children with abdominal neuroblastoma treated with definitive radiation therapy: a correlation with late toxicity. Pediatr Blood Cancer (2014) 0.75
Evaluation of radiation dose to cardiac and pulmonary tissue among patients with stage IV Wilms tumor and pulmonary metastases. Pediatr Blood Cancer (2014) 0.75
Erratum to: Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol (2015) 0.75
Patterns of presentation and failure in patients with gliomatosis cerebri treated with partial-brain radiation therapy. Cancer (2014) 0.75
Anatomic surgical management of chronic low back pain. Neuromodulation (2014) 0.75
Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg (2007) 0.75